logo
logo

Rapport Therapeutics Raises $150 Million In Series B Funding Round And Announces Key Board Appointments To Further Advance Precision Neuromedicine Platform

Rapport Therapeutics Raises $150 Million In Series B Funding Round And Announces Key Board Appointments To Further Advance Precision Neuromedicine Platform

08/24/23, 12:53 PM
Location
bahamas
Money raised
$150 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Investors
James Healy, M.D., Ph.D., Managing Partner Of Sofinnova Investments, Rapport, Johnson & Johnson Innovation – Jjdc, Inc., Arch Venture Partners, Third Rock Ventures, T. Rowe Price Associates, Inc., Surveyor Capital, Sofinnova Investments, Perceptive Advisors, Logos Capital, Goldman Sachs Asset Management, Fidelity Management & Research Company, Cormorant Asset Management
Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced that it has raised $150 million in Series B funding. Led by Cormorant Asset Management, the round includes investments from Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., and all existing investors, which include Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation – JJDC, Inc. (JJDC).

Company Info

Company
Rapport Therapeutics
Location
3601 fremont avenue north
bahamas
Additional Info
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines. The company is dedicated to developing a new class of precision neuromedicines aimed at providing patients with better alternatives to existing treatments for central nervous system disorders.

Related People